Reimagining early disease detection and treatment

Impacting millions of lives –

transforming the detection and treatment of complex diseases by harnessing the power of multi-omics data

Impacting millions of lives –

transforming the detection and treatment of complex diseases by harnessing the power of multi-omics data

PrognomiQ is developing transformative test products that enable early disease detection and treatment.

We do this by generating proprietary proteomic data at unparalleled volumes and depth of information. We then complement this extensive proteomic information with genomic, metabolomic, and other health data to discover innovative approaches to early disease detection that translate into transformative test products.

PrognomiQ is developing transformative test products that enable early disease detection and treatment.

We do this by generating proprietary proteomic data at unparalleled volumes and depth of information. We then complement this extensive proteomic information with genomic, metabolomic, and other health data to discover innovative approaches to early disease detection that translate into transformative test products.

Untapped proteomic information

Proteomics is the large-scale study of protein molecules to understand their roles in biology. Proteins perform a vast array of functions in the body and cells, including cell development and growth, and disease defense mechanisms. Until now, however, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes. These barriers have now been largely addressed through next-generation tools that enable complex proteomics at scale.

Powerful multi-omics insights

PrognomiQ leverages the latest advances in proteomics to generate direct information of a person’s biological state, including state of disease. This rich proteomic information can be further complemented by additional data sources including genomics and metabolomics. The resulting multi-omics data sets provide unparalleled levels of biological insights, including on the mechanisms of the most complex diseases.

Unlocked disease detection and treatment

We believe that early detection and treatment of complex diseases can only be unlocked through the insights provided by high-quality multi-omics data. Thus, we designed our proprietary multi-omics platform around the most robust methods to generate proteomic, genomic, and metabolomic data at scale. This powerful multi-omics platform is the engine to develop transformative healthcare products that could impact millions of lives.

OUR MISSION:

Transform the detection and early treatment of cancer and other complex diseases.

Potential Impact of Early Disease Detection

  • Earlier treatment to provide the best outcomes when cure rates remain high
  • Faster determination of how well a therapy is working
  • Earlier detection of safety issues with therapies
  • Novel insights to inform drug discovery and development

OUR MISSION:

Transform the detection and early treatment of cancer and other complex diseases.

Potential Impact of Early Disease Detection

  • Earlier treatment to provide the best outcomes when cure rates remain high
  • Faster determination of how well a therapy is working
  • Earlier detection of safety issues with therapies
  • Novel insights to inform drug discovery and development

Our management, board and scientific/clinical scientific advisors include a multidisciplinary group of world-renowned experts in proteomics, multi-omics, data sciences, and clinical medicine.

Philip Ma, PhD

Chief Executive Officer

Chinmay Belthangady, PhD

VP, Data Science

David Siewers

CFO

Bruce Wilcox, PhD

VP, Proteomics

Omid Farokhzad, MD

Chair of the Board of Directors

Tomer Berkovitz, PhD

Board of Directors

Mark McClellan, MD, PhD

Board of Directors

Charles Cantor, PhD

Scientific Advisor

Steven Carr, PhD

Scientific Advisor

Ernest Fraenkel, PhD

Scientific Advisor

Philip Kantoff, MD

Scientific and Clinical Advisor

Robert Langer, Sc.D.

Scientific Advisor

Mark Lee, MD, PhD

Scientific and Clinical Advisor

Alfred Sandrock, Jr., MD, PhD

Scientific and Clinical Advisor

Be a part of the team transforming healthcare

Careers at PrognomiQ

We are passionate about transforming healthcare by enabling the early detection and treatment of cancer and other complex diseases. Our team values passion, collaboration and the desire to tackle the toughest scientific and clinical challenges with confidence and humility. We strive to have a meaningful impact on the world.

Join us as we open new doorways into disease detection and treatment.

Be a part of the team transforming healthcare

Careers at PrognomiQ

We are passionate about transforming healthcare by enabling the early detection and treatment of cancer and other complex diseases. Our team values passion, collaboration and the desire to tackle the toughest scientific and clinical challenges with confidence and humility. We strive to have a meaningful impact on the world.

Join us as we open new doorways into disease detection and treatment.

Reach out to learn how PrognomiQ is re-imagining early disease detection